JMIR Neurotechnology

Neuromodulation of the auricular branch of the vagus nerve using low intensity focused ultrasound (LIFU) is an emerging mode of treatment for anxiety that could provide a complementary or alternative treatment modality for individuals that are refractory to conventional interventions. The proposed benefits of this technology have been largely unexamined with clinical populations. Further research is required to understand its clinical potential and utility in improving and managing moderate to severe symptoms.

A 12-month longitudinal observational study was conducted on 43 children aged 2-18 years to evaluate the effectiveness of the Cognitivebotics AI-based platform in conjunction with continuous therapy, in improving therapeutic outcomes for subjects with Autism Spectrum Disorder (ASD).

This paper presents an easy-to-use, affordable Rehabilitation Manipulandum Device (RMD) equipped with smart monitoring and assistive technologies to engage in game-based exercise and repetitive task practice. The RMD has been designed to enhance a wide range of fine motor manual dexterity skills, including thumb, finger, and wrist movements. By focusing on finger and hand functions, it extends its utility beyond basic reaching or object transfer movements. Various interchangeable 3D-printed therapy handles of different shapes and sizes can be easily attached to the RMD drive shaft. These handle movements can be utilized to engage with numerous affordable, commercially available computer games, allowing patients to practice tasks that involve varying movement amplitudes, speeds, precision, and cognitive challenges. Additionally, the device is capable of automatically recording and storing the patient's real-time performance data on any given computer, integrating assessment into treatment.

Speech features are increasingly linked to neurodegenerative and mental health conditions, offering the potential for early detection and differentiation between disorders. As interest in speech analysis grows, distinguishing between conditions becomes critical for reliable diagnosis and assessment.

Background: The emergence of generative artificial intelligence (GenAI) presents unprecedented opportunities to redefine conceptions of personhood and cognitive disability, potentially enhancing the inclusion and participation of individuals with cognitive disabilities in society.

Interest in using digital sensors to monitor post-stroke patients (PSPs) for depression, a risk factor for poor outcomes, has grown rapidly; however, little is known about behavioral phenotypes related to future mood and if patients with and without previously diagnosed depression experience similar phenotypes.

Virtual approaches to workplace concussion assessment have demonstrated value to end users. The feasibility of administering physical concussion assessment measures in a virtual context has been minimally explored and there is limited information on important psychometric properties of physical assessment measures used in virtual contexts.

Neurological disorders are the leading cause of physical and cognitive disability across the globe, currently affecting up to 15% of the world population, with the burden of chronic neurodegenerative diseases having doubled over the last 2 decades. Two decades ago, neurologists relying solely on clinical signs and basic imaging faced challenges in diagnosis and treatment. Today, the integration of artificial intelligence (AI) and bioinformatic methods is changing this landscape. This paper explores this transformative journey, emphasizing the critical role of AI in neurology, aiming to integrate a multitude of methods and thereby enhance the field of neurology. Over the past 25 years, integrating biomedical data science into medicine, particularly neurology, has fundamentally transformed how we understand, diagnose, and treat neurological diseases. Advances in genomics sequencing, the introduction of new imaging methods, the discovery of novel molecular biomarkers for nervous system function, a comprehensive understanding of immunology and neuroimmunology shaping disease subtypes, and the advent of advanced electrophysiological recording methods, alongside the digitalization of medical records and the rise of AI, all led to an unparalleled surge in data within neurology. In addition, telemedicine and web-based interactive health platforms, accelerated by the COVID-19 pandemic, have become integral to neurology practice. The real-world impact of these advancements is evident, with AI-driven analysis of imaging and genetic data leading to earlier and more accurate diagnoses of conditions such as multiple sclerosis, Parkinson disease, amyotrophic lateral sclerosis, Alzheimer disease, and more. Neuroinformatics is the key component connecting all these advances. By harnessing the power of IT and computational methods to efficiently organize, analyze, and interpret vast datasets, we can extract meaningful insights from complex neurological data, contributing to a deeper understanding of the intricate workings of the brain. In this paper, we describe the large-scale datasets that have emerged in neurology over the last 25 years and showcase the major advancements made by integrating these datasets with advanced neuroinformatic approaches for the diagnosis and treatment of neurological disorders. We further discuss challenges in integrating AI into neurology, including ethical considerations in data use, the need for further personalization of treatment, and embracing new emerging technologies like quantum computing. These developments are shaping a future where neurological care is more precise, accessible, and tailored to individual patient needs. We believe further advancements in AI will bridge traditional medical disciplines and cutting-edge technology, navigating the complexities of neurological data and steering medicine toward a future of more precise, accessible, and patient-centric health care.

Developing new clinical measures for degenerative cervical myelopathy (DCM) is an AO Spine RECODE-DCM research priority. Difficulties detecting DCM, and changes in DCM, cause diagnostic and treatment delays in clinical settings and heightened costs in clinical trials due to elevated recruitment targets. Digital outcome measures can tackle these challenges due to their ability to measure disease remotely, repeatedly, and more economically.

As a novel technology frontier, neurotechnology is revolutionizing our perceptions of the brain and nervous system. With growing private and public investments, a thriving ecosystem of direct-to-consumer neurotechnologies has also emerged. These technologies are increasingly being introduced in many parts of the world, including Africa. However, as the use of this technology expands, neuroethics and ethics of emerging technology scholars are bringing attention to the critical concerns it raises. These concerns are largely not new but are uniquely amplified by the novelty of technology. They include ethical and legal issues such as privacy, human rights, human identity, bias, autonomy, and safety, which are part of the artificial intelligence ethics discourse. Most importantly, there is an obvious lack of regulatory oversight and a dearth of literature on the consideration of contextual ethical principles in the design and application of neurotechnology in Africa. This paper highlights lessons African stakeholders need to learn from the ethics and governance of artificial intelligence to ensure the design of ethically responsible and socially acceptable neurotechnology in and for Africa.

Low sleep quality is a common symptom of multiple sclerosis (MS) and substantially decreases patients’ quality of life. The autonomic nervous system (ANS) is crucial to healthy sleep, and the transition from wake to sleep produces the largest shift in autonomic activity we experience every day. For patients with MS, the ANS is often impaired. The relationship between the ANS and perceived sleep quality in patients with MS remains elusive.

Recreational and leisure activities significantly contribute to the well-being of older adults, positively impacting physical, cognitive, and mental health. However, limited mobility and cognitive decline often impede access to these activities, particularly for individuals living with dementia. With the increasing availability of digital technologies, there is a rising interest in using technology to deliver recreation and leisure activities for cognitively impaired individuals, acknowledging its potential to provide diverse experiences. The COVID-19 pandemic further highlighted the need for virtual program delivery, especially for individuals in long-term care settings, leading to the development of tools like the Dementia Isolation Toolkit aimed at supporting compassionate isolation. To better support future implementations of the DIT, our rapid scoping review explores evidence-based, technology-enabled recreation programs for older adults with cognitive impairments, which promote well-being.